Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioharvest Sciences Inc C.BHSC

Alternate Symbol(s):  BHST

BioHarvest Sciences Inc. is a Canada-based biotechnology company. The Company offers Botanical Synthesis, its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. The Company is leveraging its Botanical Synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. The Company operates through two segments: Nutraceuticals and Pharmaceuticals. The Company offers a polyphenol/antioxidant superfruit product called VINIA, which is a red grape powder that supplies the benefits of red wine consumption but without the sugar, calories and alcohol found in wine.


CSE:BHSC - Post by User

Post by Betteryear2on Jan 31, 2022 2:06pm
194 Views
Post# 34379930

The Power Play by The Market Herald Releases Interviews

The Power Play by The Market Herald Releases Interviews

(Sponsored)

BioHarvest Sciences is a biotechnology company that has built a BioFarming technology platform that grows plant cells in their natural structure in proprietary bioreactors. The company is estimating 2022 revenue to be between US$5M-$7M and is targeting 1H 2022 for the first sales of its cannabis product. Ilan Sobel, CEO of BioHarvest sat down with Dave Jackson to share BioHarvest's vision of bringing the power of plants to the people.

For the full interview with Ilan Sobel and to learn more about BioHarvest Sciences, click here.

<< Previous
Bullboard Posts
Next >>